Annals of Oncology Advance Access published online on March 6, 2006
Annals of Oncology, doi:10.1093/annonc/mdj130
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Mayo Clinic, Jacksonville, FL, USA
* To whom correspondence should be addressed. Background: A one-stage phase II trial was conducted to assess the tumor response rate and toxicity profile of single agent oral vinorelbine as first or second-line chemotherapy for women at least 65 years of age with metastatic breast cancer. Patients and methods: Twenty-five patients with metastatic breast cancer aged Results: Twenty-five patients were included and evaluable for analysis. One patient (4%) achieved a partial response (PR) that lasted for more than 13 months. Two additional patients remained stable for at least 6 months for a clinical benefit rate (PR + stable disease) of 12%. The 1-year survival rate was estimated to be 48% (95% CI 30% to 74.5%). Median time to progression was estimated to be 4.7 months (95% CI 2.0-5.5 months) and the 9-month disease progression-free rate was estimated to be 8% (95% CI 30.9% to 74.5%). The treatment was fairly well tolerated with grade 3 neutropenia in 12.5%, fatigue in 12.5% of the patients, and grade 2 neuromotor and neurosensory toxicities in 12.5% and 8.3%, respectively. Conclusion: Oral vinorelbine as a single agent at these dose and schedule in this population of women
Received July 5, 2005
Revised November 24, 2005
Accepted December 2, 2005
original article
Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients
M. Baweja 1,
V. J. Suman 2,
T. R. Fitch 3,
J. A. Mailliard 4,
A. Bernath 5,
K. M. Rowland 6,
S. R. Alberts 2,
J. S. Kaur 2,
and
E. A. Perez 1 *
65 years of age: an NCCTG study
2 Mayo Clinic, Rochester, MN, USA
3 Mayo Clinic, Scottsdale, AZ, USA
4 Missouri Valley Cancer Consortium CCOP, Omaha, NE, USA
5 Geisinger Medical Center, Danville, PA, USA
6 Carle Cancer Center, Urbana, IL, USA
E. A. Perez, E-mail: perez.edith{at}mayo.edu
Abstract 
65 years of age were enrolled to receive oral vinorelbine on a weekly basis. The oral vinorelbine was given at 60 mg/m2 weekly for the first four doses and was increased to 70 mg/m2 for the subsequent administrations if there was no grade 4 neutropenia or no more than one episode of grade 3 neutropenia. Therapy was continued until progression or intolerable toxicity.65 years is well tolerated but has a low level of objective efficacy for the treatment of metastatic breast cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Findlay, G. von Minckwitz, and A. Wardley Effective oral chemotherapy for breast cancer: pillars of strength Ann. Onc., February 1, 2008; 19(2): 212 - 222. [Abstract] [Full Text] [PDF]
|
|